DOI:
10.1055/s-00035024
Thrombosis and Haemostasis
LinksClose Window
References
Alexander JH, Becker RC, Bhatt DL. et al; APPRAISE Steering Committee and Investigators.
Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.
Circulation 2009;
119 (22) 2877-2885
We do not assume any responsibility for the contents of the web pages of other providers.